Startup Rise EU News’ Post

Biotech funding is the financial backing of biotechnology research and development, usually through private investors or venture capital firms. Some notable biotech funding deals in recent months include ¹: - Recent biotech pre-seed funding: - NXI Therapeutics (Switzerland): $3.96 million, for immunotherapies - Recent biotech seed funding: - Advesya (France): $23 million, for cancer therapies - Cumulus Oncology (United Kingdom): $11.45 million, for cancer drug discovery - DISCO Pharmaceuticals (Germany): $21.75 million, for drug discovery - Recent biotech series A funding: - Claris Bio (United States): $57 million, for corneal therapies - Resalis Therapeutics (Italy): $10.95 million, for non-coded RNA-based therapeutics - OnCusp Therapeutics (United States): $100 million, for oncology assets - Recent biotech series B funding: - Vico Therapeutics (Netherlands): $60 million, for RNA modulation - Full-Life Technologies (China, Belgium): $47.3 million, for radionuclide drug conjugates - Avistone Biotechnology (China): $140 million, for targeted cancer drugs #biotech #funding #venturecapital #investing #biotechnology #lifesciences #healthcare #innovation #startups #biotechnews #pharmaceuticals #medtech #biotechindustry #investmentnews #fundingnews #biotechcompanies #biotechinvesting

On February 5th, Dr. Cyril Sarrauste de Menthiere , one of our esteemed scientific advisors and patient partners, had the honor of being invited to a roundtable organized by the Paris Saclay Cancer Cluster : Why and How Work with Patients from the Earliest Stages of an Innovative Project?   He eloquently emphasized the importance for startups and pharmaceutical companies to collaborate with patient partners, using the concrete example of ReACT Therapeutics.   From its inception, the co-founders of ReACT Therapeutics, Emile Roussel, PhD, Lise Clément-Demange & Renaud VAILLANT, made the bold choice to integrate a patient partner into their scientific committee. But why?   #1 Developing a drug candidate for patients cannot be done without patients.  #2 The patient partner brings a wealth of information, firsthand experiences, and crucial insights to the startup.  #3 They participate in general meetings and can be called upon to address specific needs.  #4 The patient partner plays a key role in recruiting patients for clinical trials.  #5 They contribute to promoting the startup, its team, and its solution within their network. #PatientPartnership #HealthcareInnovation #PatientEngagement #Startups #Pharmaceuticals #CancerResearch #PatientExperience #HealthcareCollaboration #ScientificAdvisors #MedicalInnovation #ResearchPartnership #PatientAdvocacy #HealthcareNetworking #DrugDevelopment #HealthcareInsights

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis. Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. It's become a popular drug target in recent years, and was backbone of a $4 billion deal last year. What do you think of TYK2? Is there still room for more TYK2 inhibitors in psoriasis, or is the field too crowded? #biotech #pharma #drugdevelopment #TYK2 #inflammation #autoimmunedisease #psoriasis #clinicaltrials #seriesc #fundraising #vc #venturecapital STAT

In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today’s most lucrative medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Enbrel, might not have become so without mergers and acquisitions. The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market.

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

Taiwan Life Sciences Biweekly - July 15, 2024 🔊 Foreseen Biotechnology Strikes $1.03B Deal with Ipsen SA of Paris for First-in-Class ADC 🔊 (Thailand) Saha Group collaborates with (Taiwan's) Quark Biosciences to venture into biotechnology 🔊 BIO Asia–Taiwan 2024 to Set Record, Aims to Propel Taiwanese Companies onto the International Stage, Focuses on Cell Therapy and Regenerative Medicine 🔊 Synmosa Biopharma obtains Celltrion's drug transfer rights for Taiwan and Hong Kong, completing over 20 drug license transfers 🔊 Foresee Pharmaceuticals Co., Ltd.'s New Prostate Cancer Drug CAMCEVI Receives Approval for Market in Israel 🔊 2024 Taiwan BIO Awards Announced 19 Winners: The Outstanding Company Award won by Lotus Pharmaceutical Co., Ltd, PharmaEssentia, and Bonraybio. The Emerging Company Award given to Pharmosa Biopharm Inc, TSH Biopharm Corporation Ltd, Steminent Biotherapeutics, Onyx Healthcare , and 明基透析科技. The Startup Award went to Acepodia, ImmunAdd Inc., Sunhawk Vision Biotech, Elixiron Immunotherapeutics, BioGend Therapeutics (TWSE 6733), BRAXX Biotech Co., Ltd., and Protect Biotech... 🔊 Ever Supreme Bio Technology Co., Ltd.'s World's First AI-Based CAR-T Drug Screening Approved for Clinical Trials by TFDA 🔊 Lin BioScience's Acute Leukemia New Drug LBS-007 Receives US FDA Orphan Drug Designation 🔊 Diamond Biofund Inc. Establishes European Investment Bridge, Signs MOU with French Venture Capital Fund AdBio Partners. 🔊 Exosome market rapidly growing, Taiwanese companies positioned to enter. For more details, please visit: https://lnkd.in/efTm2G4S

𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report encompasses an overview of the development of the Cancer Janus Kinase Inhibitors industry chain, focusing on its applications in Hospitals (Ruxolitinib, Momelotinib) and Ambulatory Surgical Centers (Ruxolitinib, Momelotinib). It highlights key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, hot applications, and market trends of Cancer Janus Kinase Inhibitors. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/guSqh8-w *𝗕𝘆 𝗧𝘆𝗽𝗲: Ruxolitinib, Momelotinib, Lestaurtinib, Pacritinib, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Ambulatory Surgical Centers, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, Asana BioSciences, LLC, AstraZeneca, Celonic Group, Dynamic Pharma S.A. – Δυναμική Φαρμακαποθήκη Α.Ε., Eli Lilly and Company, Gilead Sciences, Hanmi Pharmaceuticals, Incyte, Kyowa Hakko USA, Moleculin Biotech, Inc., Pfizer, Portola Pharmaceuticals #januskinaseinhibitors #cancerresearch #cancertreatment #oncology #drugdevelopment #cancertherapeutics #pharmaceuticals #biomedicalscience #jakinhibitors #precisionmedicine

🚀 Kailera Therapeutics has launched with a $400M Series A The round was co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital. The funds will accelerate the development of KAI-9531, an injectable GLP-1 receptor agonist acquired from Jiangsu Hengrui Pharmaceuticals in May this year. KAI-9531 has already completed early clinical trials in China and is now advancing into Phase 3 to target obesity and metabolic disorders. 🌍💉 The biotech will be led by CEO Ron Renaud, who previously guided Cerevel Therapeutics to its acquisition by AbbVie for $8.7 billion in December 2023. In addition to KAI-9531, Kailera has three other GLP-1 agonists in development, including KAI-7535, (oral small molecule entering phase 2), and two preclinical assets. While Novo Nordisk and Eli Lilly currently dominate the GLP-1 market, the competition is intensifying. Roche and Viking Therapeutics are developing dual GLP-1 and GIP agonists, similar to Lilly’s Zepbound, which target both obesity and diabetes. 🚀 Moreover, startups like OrsoBio, SixPeaks Bio, and BioAge Labs have raised significant private funding to enter the space. BioAge Labs, which shifted its focus to obesity drug research, recently had a successful IPO, signaling strong investor confidence in the growing metabolic drug market. 📊 The global GLP-1 receptor agonist market is expected to reach $16.8 billion by 2028, driven by increasing demand for innovative treatments targeting both diabetes and obesity. 🤔As more biotechs develop GLP-1 therapies, it will be interesting to see how emerging players could challenge the dominance of established giants in the obesity treatment market...

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

🔬Messaginglab and Degron Therapeutics Partnered on a $1.2B Collaboration Announcement - With Big Results 🧬 We're thrilled to have collaborated with Degron Therapeutics - an emerging leader in the discovery of small molecule, molecular glue degrader drugs - on their recent press release announcing their $1.2B collaboration with Takeda. Molecular glue degraders are small molecule drugs that act as adhesives by bringing a disease target protein to another protein called E3 ligase, which is a component of a protein degradation machinery. As a result, the disease target protein is “tagged” as trash and degraded in the cell.   This approach has the potential to target previously undruggable proteins, opening new avenues for treating challenging diseases in cancer, inflammation, neurodegenerative and other disorders. Messaginglab's Impact: 💡Translating Difficult Science: We simplified the complexity of molecular glues to help Degron reach a broader audience. Our approach resonated widely for investors, partners, and the public. 💡Amplifying Media Presence: Through targeted outreach, we secured coverage in 20 top life science and pharma publications, including Biocentury, BioWorld, Chemical & Engineering News, and Fierce Biotech. This expanded visibility positioned Degron as a key player in biotech. 💡Crafting a Compelling Corporate Narrative: Beyond the $1.2B deal, we highlighted Degron's mission to revolutionize drug discovery. We created an emotional connection by focusing on the impact on patients' lives, elevating Degron's story above financial metrics. 💡Showcasing Thought Leadership: We positioned Degron's co-founder and CEO, Lily Zou, as a visionary leader. Her quotes and media accessibility added a human touch to the company's technological breakthroughs, building trust and credibility. 💡Driving Meaningful Engagement: Our success went beyond metrics. We focused on generating high-quality media coverage that sparked conversations among key stakeholders in the biotech community. The Power of Partnership: We're proud to have been a part of this groundbreaking work. Our collaboration with Degron Therapeutics showcases Messaginglab's ability to elevate complex science through strategic communication. #MediaRelations #BiopharmaNews